泰吉华单抗治疗IgA血管炎肾病的疗效：两例报告
Efficacy of Telitacicept in treating IgA vasculitis nephritis: a two-case report.
作者信息
Li Shuang-Xi, Hu Rui-Kang, Kong De-Liang, Xu Jing, Bian Qi, Guo Zhi-Yong, Mei Xiao-Bin
机构信息
Department of Nephrology, Changhai Hospital, The Naval Medical University, Shanghai, China.
Medical School of Chinese People's Liberation Army (PLA), Beijing, China.
出版信息
Front Immunol. 2025 May 1;16:1564242. doi: 10.3389/fimmu.2025.1564242. eCollection 2025.
Abstract
Telitacicept, a B lymphocyte stimulator/A proliferation-inducing ligand dual-target fusion protein, mainly used for IgA nephropathy and systemic lupus erythematosus. We present two cases where adult patients with IgA vasculitis (IgAV) nephritis were successfully treated with Telitacicept, experienced no adverse reactions during the follow-up. Therefore, Telitacicept represents a promising additional treatment option for patients suffering from IgA vasculitis (IgAV).
摘要
泰吉华昔单抗是一种B淋巴细胞刺激因子/增殖诱导配体双靶点融合蛋白，主要用于治疗IgA肾病和系统性红斑狼疮。我们报告了两例IgA血管炎（IgAV）肾炎成年患者使用泰吉华昔单抗成功治疗的病例，随访期间未出现不良反应。因此，泰吉华昔单抗为患有IgA血管炎（IgAV）的患者提供了一种有前景的额外治疗选择。
相似文献
1
Efficacy of Telitacicept in treating IgA vasculitis nephritis: a two-case report.泰吉华单抗治疗IgA血管炎肾病的疗效：两例报告
Front Immunol. 2025 May 1;16:1564242. doi: 10.3389/fimmu.2025.1564242. eCollection 2025.
2
Telitacicept as a BAFF/APRIL dual inhibitor: efficacy and safety in reducing proteinuria for refractory childhood IgA vasculitis nephritis.泰利妥昔单抗作为一种BAFF/APRIL双抑制剂：在降低难治性儿童IgA血管炎肾病蛋白尿方面的疗效和安全性
Pediatr Nephrol. 2025 Apr 11. doi: 10.1007/s00467-025-06769-3.
3
Successful outcome of a refractory IgA vasculitis nephritis in children treated with telitacicept.用泰吉华单抗治疗的儿童难治性IgA血管炎肾炎的成功结果
CEN Case Rep. 2025 Mar 1. doi: 10.1007/s13730-025-00983-6.
4
Exploring the shared molecular mechanisms of primary hypertension and IgA vasculitis through a case report and combining bioinformatics analysis.通过病例报告并结合生物信息学分析探索原发性高血压和IgA血管炎的共同分子机制。
Front Immunol. 2025 Jun 6;16:1596174. doi: 10.3389/fimmu.2025.1596174. eCollection 2025.
5
IgA vasculitis.IgA 血管炎。
Semin Immunopathol. 2021 Oct;43(5):729-738. doi: 10.1007/s00281-021-00874-9. Epub 2021 Jun 25.
6
[Immunoglobulin A vasculitis (IgAV)].免疫球蛋白A血管炎（IgAV）
Z Rheumatol. 2023 Sep;82(7):587-598. doi: 10.1007/s00393-023-01355-0. Epub 2023 Jun 2.
7
A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP).IgA 血管炎（过敏性紫癜）儿童肾炎潜在药物治疗的叙述性综述。
Clin Rheumatol. 2023 Dec;42(12):3189-3200. doi: 10.1007/s10067-023-06781-8. Epub 2023 Sep 27.
8
Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: a systematic review and meta-analysis.中国系统性红斑狼疮患者中不同推荐剂量泰它西普的疗效和安全性比较：一项系统评价和荟萃分析
Front Immunol. 2025 Jan 10;15:1472292. doi: 10.3389/fimmu.2024.1472292. eCollection 2024.
9
IgA vasculitis after COVID-19: a case-based review.COVID-19 后 IgA 血管炎：基于病例的综述。
Rheumatol Int. 2024 Jul;44(7):1353-1357. doi: 10.1007/s00296-024-05606-4. Epub 2024 May 13.
10
Therapy for children with henoch-schonlein purpura nephritis: a systematic review.过敏性紫癜性肾炎患儿的治疗：一项系统评价
ScientificWorldJournal. 2007 Jan 10;7:20-30. doi: 10.1100/tsw.2007.23.
本文引用的文献
1
Efficacy and safety of telitacicept, a BLyS/APRIL dual inhibitor, in the treatment of IgA nephropathy: a retrospective case-control study.贝利木单抗/增殖诱导配体双重抑制剂泰吉华单抗治疗IgA肾病的疗效和安全性：一项回顾性病例对照研究
Clin Kidney J. 2024 Sep 13;17(10):sfae285. doi: 10.1093/ckj/sfae285. eCollection 2024 Oct.
2
Efficacy and Safety of Telitacicept in IgA Nephropathy: A Retrospective, Multicenter Study.泰它西普治疗IgA肾病的疗效与安全性：一项回顾性多中心研究
Nephron. 2025;149(1):1-10. doi: 10.1159/000540326. Epub 2024 Sep 9.
3
Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA Nephropathy.泰它西普对IgA肾病患者循环血中Gd-IgA1及含IgA免疫复合物的影响。
Kidney Int Rep. 2024 Jan 10;9(4):1067-1071. doi: 10.1016/j.ekir.2024.01.003. eCollection 2024 Apr.
4
The efficacy and safety of tacrolimus in treating refractory IgA vasculitis nephritis: a single-center retrospective study on 16 cases.他克莫司治疗难治性IgA血管炎肾病的疗效及安全性：一项对16例患者的单中心回顾性研究
Clin Kidney J. 2024 Apr 16;17(5):sfae115. doi: 10.1093/ckj/sfae115. eCollection 2024 May.
5
A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.Sibeprenlimab 治疗 IgA 肾病患者的 II 期临床试验。
N Engl J Med. 2024 Jan 4;390(1):20-31. doi: 10.1056/NEJMoa2305635. Epub 2023 Nov 2.
6
Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria.泰吉华单抗治疗持续性蛋白尿IgA肾病患者的随机2期试验
Kidney Int Rep. 2022 Dec 29;8(3):499-506. doi: 10.1016/j.ekir.2022.12.014. eCollection 2023 Mar.
7
Mycophenolate Mofetil for Severe IgA Vasculitis Nephropathy in Children: An Observational Study.霉酚酸酯治疗儿童重症IgA血管炎肾病：一项观察性研究。
Kidney Med. 2022 Aug 12;4(10):100534. doi: 10.1016/j.xkme.2022.100534. eCollection 2022 Oct.
8
Rituximab in severe immunoglobulin-A vasculitis (Henoch-Schönlein) with aggressive nephritis.利妥昔单抗治疗严重免疫球蛋白 A 血管炎（过敏性紫癜）合并侵袭性肾炎。
Clin Exp Rheumatol. 2020 Mar-Apr;38 Suppl 124(2):195-200. Epub 2020 May 22.
9
European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative.欧洲基于共识的免疫球蛋白 A 血管炎诊断和治疗建议——SHARE 倡议。
Rheumatology (Oxford). 2019 Sep 1;58(9):1607-1616. doi: 10.1093/rheumatology/kez041.
10
Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study.IgA 肾病或 IgA 血管炎儿童及成人的临床特征与治疗模式：CureGN 研究结果
Kidney Int Rep. 2018 Aug 3;3(6):1373-1384. doi: 10.1016/j.ekir.2018.07.021. eCollection 2018 Nov.
Zotero 插件